Skye Bioscience, Inc.
SKYE
$0.72
$0.068.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.31% | 0.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.30% | -27.29% | |||
| Operating Income | -12.30% | 27.29% | |||
| Income Before Tax | -13.23% | 27.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.23% | 27.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.23% | 27.63% | |||
| EBIT | -12.30% | 27.29% | |||
| EBITDA | -12.46% | 27.53% | |||
| EPS Basic | -13.18% | 27.63% | |||
| Normalized Basic EPS | -13.78% | 27.48% | |||
| EPS Diluted | -13.18% | 27.63% | |||
| Normalized Diluted EPS | -13.78% | 27.48% | |||
| Average Basic Shares Outstanding | 0.02% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||